Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model

Jennifer A. Flemming, Ju D ong Yang, Eric Vittinghoff, W. Ray Kim, Norah A. Terrault

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

BACKGROUND: All patients with cirrhosis are at risk of developing hepatocellular carcinoma (HCC). This risk is not uniform because other patient-related factors influence the risk of HCC. The objective of the current study was to develop an HCC risk prediction model to estimate the 1-year probability of HCC to assist with patient counseling.

METHODS: Between 2002 and 2011, a cohort of 34,932 patients with cirrhosis was identified from a national liver transplantation waitlist database from the United States. Cox proportional hazards regression methods were used to develop and validate a risk prediction model for incident HCC. In the validation cohort, discrimination and calibration of the model was examined. External validation was conducted using patients with cirrhosis who were enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) study.

RESULTS: HCC developed in 1960 patients (5.6%) during a median follow-up of 1.3 years (interquartile range, 0.47 years-2.83 years). Six baseline clinical variables, including age, diabetes, race, etiology of cirrhosis, sex, and severity (ADRESS) of liver dysfunction were independently associated with HCC and were used to develop the ADRESS-HCC risk model. C-indices in the derivation and internal validation cohorts were 0.704 and 0.691, respectively. In the validation cohort, the predicted cumulative incidence of HCC by the ADRESS-HCC model closely matched the observed data. In patients with cirrhosis in the HALT-C cohort, the model stratified patients correctly according to the risk of developing HCC within 5 years.

CONCLUSIONS: The ADRESS-HCC risk model is a useful tool for predicting the 1-year risk of HCC among patients with cirrhosis.

Original languageEnglish (US)
Pages (from-to)3485-3493
Number of pages9
JournalCancer
Volume120
Issue number22
DOIs
StatePublished - Nov 15 2014
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Fibrosis
Hepatitis C
Antiviral Agents
Liver Transplantation
Calibration
Liver Diseases
Counseling
Databases
Incidence

Keywords

  • cirrhosis
  • hepatocellular carcinoma
  • liver cancer
  • risk factors
  • risk model
  • Scientific Registry of Transplant Recipients (SRTR)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Flemming, J. A., Yang, J. D. O., Vittinghoff, E., Kim, W. R., & Terrault, N. A. (2014). Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer, 120(22), 3485-3493. https://doi.org/10.1002/cncr.28832

Risk prediction of hepatocellular carcinoma in patients with cirrhosis : the ADRESS-HCC risk model. / Flemming, Jennifer A.; Yang, Ju D ong; Vittinghoff, Eric; Kim, W. Ray; Terrault, Norah A.

In: Cancer, Vol. 120, No. 22, 15.11.2014, p. 3485-3493.

Research output: Contribution to journalArticle

Flemming, JA, Yang, JDO, Vittinghoff, E, Kim, WR & Terrault, NA 2014, 'Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model', Cancer, vol. 120, no. 22, pp. 3485-3493. https://doi.org/10.1002/cncr.28832
Flemming JA, Yang JDO, Vittinghoff E, Kim WR, Terrault NA. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer. 2014 Nov 15;120(22):3485-3493. https://doi.org/10.1002/cncr.28832
Flemming, Jennifer A. ; Yang, Ju D ong ; Vittinghoff, Eric ; Kim, W. Ray ; Terrault, Norah A. / Risk prediction of hepatocellular carcinoma in patients with cirrhosis : the ADRESS-HCC risk model. In: Cancer. 2014 ; Vol. 120, No. 22. pp. 3485-3493.
@article{ae5f250b228e465594c6ae1182eda7f4,
title = "Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model",
abstract = "BACKGROUND: All patients with cirrhosis are at risk of developing hepatocellular carcinoma (HCC). This risk is not uniform because other patient-related factors influence the risk of HCC. The objective of the current study was to develop an HCC risk prediction model to estimate the 1-year probability of HCC to assist with patient counseling.METHODS: Between 2002 and 2011, a cohort of 34,932 patients with cirrhosis was identified from a national liver transplantation waitlist database from the United States. Cox proportional hazards regression methods were used to develop and validate a risk prediction model for incident HCC. In the validation cohort, discrimination and calibration of the model was examined. External validation was conducted using patients with cirrhosis who were enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) study.RESULTS: HCC developed in 1960 patients (5.6{\%}) during a median follow-up of 1.3 years (interquartile range, 0.47 years-2.83 years). Six baseline clinical variables, including age, diabetes, race, etiology of cirrhosis, sex, and severity (ADRESS) of liver dysfunction were independently associated with HCC and were used to develop the ADRESS-HCC risk model. C-indices in the derivation and internal validation cohorts were 0.704 and 0.691, respectively. In the validation cohort, the predicted cumulative incidence of HCC by the ADRESS-HCC model closely matched the observed data. In patients with cirrhosis in the HALT-C cohort, the model stratified patients correctly according to the risk of developing HCC within 5 years.CONCLUSIONS: The ADRESS-HCC risk model is a useful tool for predicting the 1-year risk of HCC among patients with cirrhosis.",
keywords = "cirrhosis, hepatocellular carcinoma, liver cancer, risk factors, risk model, Scientific Registry of Transplant Recipients (SRTR)",
author = "Flemming, {Jennifer A.} and Yang, {Ju D ong} and Eric Vittinghoff and Kim, {W. Ray} and Terrault, {Norah A.}",
year = "2014",
month = "11",
day = "15",
doi = "10.1002/cncr.28832",
language = "English (US)",
volume = "120",
pages = "3485--3493",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "22",

}

TY - JOUR

T1 - Risk prediction of hepatocellular carcinoma in patients with cirrhosis

T2 - the ADRESS-HCC risk model

AU - Flemming, Jennifer A.

AU - Yang, Ju D ong

AU - Vittinghoff, Eric

AU - Kim, W. Ray

AU - Terrault, Norah A.

PY - 2014/11/15

Y1 - 2014/11/15

N2 - BACKGROUND: All patients with cirrhosis are at risk of developing hepatocellular carcinoma (HCC). This risk is not uniform because other patient-related factors influence the risk of HCC. The objective of the current study was to develop an HCC risk prediction model to estimate the 1-year probability of HCC to assist with patient counseling.METHODS: Between 2002 and 2011, a cohort of 34,932 patients with cirrhosis was identified from a national liver transplantation waitlist database from the United States. Cox proportional hazards regression methods were used to develop and validate a risk prediction model for incident HCC. In the validation cohort, discrimination and calibration of the model was examined. External validation was conducted using patients with cirrhosis who were enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) study.RESULTS: HCC developed in 1960 patients (5.6%) during a median follow-up of 1.3 years (interquartile range, 0.47 years-2.83 years). Six baseline clinical variables, including age, diabetes, race, etiology of cirrhosis, sex, and severity (ADRESS) of liver dysfunction were independently associated with HCC and were used to develop the ADRESS-HCC risk model. C-indices in the derivation and internal validation cohorts were 0.704 and 0.691, respectively. In the validation cohort, the predicted cumulative incidence of HCC by the ADRESS-HCC model closely matched the observed data. In patients with cirrhosis in the HALT-C cohort, the model stratified patients correctly according to the risk of developing HCC within 5 years.CONCLUSIONS: The ADRESS-HCC risk model is a useful tool for predicting the 1-year risk of HCC among patients with cirrhosis.

AB - BACKGROUND: All patients with cirrhosis are at risk of developing hepatocellular carcinoma (HCC). This risk is not uniform because other patient-related factors influence the risk of HCC. The objective of the current study was to develop an HCC risk prediction model to estimate the 1-year probability of HCC to assist with patient counseling.METHODS: Between 2002 and 2011, a cohort of 34,932 patients with cirrhosis was identified from a national liver transplantation waitlist database from the United States. Cox proportional hazards regression methods were used to develop and validate a risk prediction model for incident HCC. In the validation cohort, discrimination and calibration of the model was examined. External validation was conducted using patients with cirrhosis who were enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) study.RESULTS: HCC developed in 1960 patients (5.6%) during a median follow-up of 1.3 years (interquartile range, 0.47 years-2.83 years). Six baseline clinical variables, including age, diabetes, race, etiology of cirrhosis, sex, and severity (ADRESS) of liver dysfunction were independently associated with HCC and were used to develop the ADRESS-HCC risk model. C-indices in the derivation and internal validation cohorts were 0.704 and 0.691, respectively. In the validation cohort, the predicted cumulative incidence of HCC by the ADRESS-HCC model closely matched the observed data. In patients with cirrhosis in the HALT-C cohort, the model stratified patients correctly according to the risk of developing HCC within 5 years.CONCLUSIONS: The ADRESS-HCC risk model is a useful tool for predicting the 1-year risk of HCC among patients with cirrhosis.

KW - cirrhosis

KW - hepatocellular carcinoma

KW - liver cancer

KW - risk factors

KW - risk model

KW - Scientific Registry of Transplant Recipients (SRTR)

UR - http://www.scopus.com/inward/record.url?scp=84924928534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924928534&partnerID=8YFLogxK

U2 - 10.1002/cncr.28832

DO - 10.1002/cncr.28832

M3 - Article

C2 - 25042049

VL - 120

SP - 3485

EP - 3493

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 22

ER -